When the U.S. Food and Drug Administration first introduced Project Optimus, it marked a decisive shift in how oncology drugs are developed. Several years on, its impact is no longer theoretical; it is actively reshaping dose optimisation and trial design. For sponsors and CROs alike, understanding how to operationalise this initiative is now critical.
What is Project Optimus?
Project Optimus is an initiative from the FDA’s Oncology Centre of Excellence aimed at reforming dose selection in oncology drug development.
Historically, oncology trials followed a “maximum tolerated dose” (MTD) approach, escalating the dose until toxicity limits were reached. While effective for cytotoxic chemotherapies, this model is often unsuitable for modern targeted therapies and immuno-oncology agents.
Project Optimus instead emphasises:
- Identification of optimal biological dose, not just the highest tolerable dose
- Use of dose-ranging studies early in development
- Integration of pharmacokinetics (PK), pharmacodynamics (PD), and exposure-response data
- Continuous dose refinement across clinical phases
The goal is simple but significant: enhancing oncology outcomes through better dose selection.
Why Project Optimus Was Needed
The shift didn’t happen in a vacuum. Advances in precision medicine exposed key limitations in traditional oncology development:
- Targeted therapies often show plateauing efficacy at lower doses
- Higher doses can increase chronic toxicity without added benefit
- Patients remain on treatment longer, making long-term tolerability critical
Simply put, giving patients a higher dose does not necessarily lead to better outcomes. It may only increase side effects, for example, so the focus has shifted towards identifying the dose that provides the greatest benefit while minimising harm.
Regulators recognised that suboptimal dosing could compromise both efficacy and quality of life, prompting a rethink of long-standing development paradigms.
How Project Optimus Is Changing Clinical Trial Design
Several years on, the influence of Project Optimus is visible across early-phase and late-phase development.
1. Expanded Phase I Designs
Dose escalation alone is no longer sufficient. Sponsors are now expected to incorporate:
- Randomised dose-expansion cohorts
- Multiple dose arms evaluated in parallel
- Early exploration of exposure-response relationships
This aligns closely with modern clinical pharmacology studies, where PK/PD modelling plays a central role.
2. Greater Emphasis on Dose Justification
Regulatory submissions must now include:
- Robust dose optimisation strategies
- Justification for selected doses based on clinical and modelling data
- Evidence that alternative doses were adequately explored
This increases the importance of integrated clinical pharmacology support studies throughout development.
3. Seamless Development Approaches
Rather than relying on rigid phase transitions, clinical trials are now being designed with greater flexibility, allowing them to adapt as new data emerges. Dose-finding and early efficacy assessments are increasingly combined within the same study, enabling more efficient progression through development. This approach supports faster, evidence-based decision-making and reflects a broader shift in early-phase drug development under Project Optimus.
Operational Challenges for Sponsors
While the scientific rationale behind Project Optimus is clear, putting it into practice introduces added complexity. Early-phase trials are becoming larger and more intricate, often including multiple dose arms and adaptive elements within a single study, which increases the burden on planning and execution.
There is also a greater need for real-time data analysis and modelling. Sponsors must assess emerging PK/PD and exposure-response data on an ongoing basis, requiring faster, more integrated decision-making.
At the same time, closer collaboration across clinical, pharmacology, biostatistics, and regulatory teams is essential to ensure a cohesive approach to dose optimisation. Regulatory interactions are also more frequent and detailed, with increased expectations around dose justification.
Without the right expertise and infrastructure, these added demands can place pressure on timelines rather than improve them.
Enhancing Oncology Outcomes with Project Optimus
Ultimately, Project Optimus represents more than a regulatory shift. It reflects a more patient-focused approach to oncology drug development. By prioritising optimal dosing rather than simply the highest tolerable dose, it aims to improve treatment tolerability while maintaining, or even enhancing, clinical efficacy. This approach also supports longer treatment durations where appropriate, helping to ensure patients can remain on therapy and derive sustained benefit.
At its core, this is what enhancing oncology outcomes through Project Optimus looks like in practice: delivering therapies that are not only effective but also better suited to the realities of long-term patient care.
The Future of Oncology with Project Optimus
Looking ahead, the future of oncology with Project Optimus will be shaped by more data-driven and adaptive development strategies. There will be increased use of model-informed drug development (MIDD), alongside a greater reliance on biomarkers and precision dosing approaches to guide decision-making. Trial designs are expected to become more flexible and innovative, with earlier and more collaborative engagement with regulators throughout development.
As these approaches continue to evolve, dose optimisation will move beyond a regulatory expectation to become a clear competitive advantage in oncology drug development.
How Simbec-Orion Can Support Your Programme
Navigating the requirements of Project Optimus requires more than scientific understanding; it demands the right operational expertise and integrated capabilities. From early phase strategy through to execution, having the right partner in place can make a meaningful difference to both timelines and outcomes.
At Simbec-Orion, we support sponsors with tailored Phase I trial design, clinical pharmacology expertise, and the delivery of complex, adaptive studies aligned with evolving regulatory expectations. Our integrated approach ensures that dose optimisation strategies are not only well-designed but also effectively implemented in practice.
Contact our expert team today if you are looking to strengthen your approach to dose optimisation and align with Project Optimus